The latest research result, the immune score test, can now more accurately define the disease progression of colon cancer patients. According to an international study of more than 2,500 patients, immune scores have been shown to be effective in predicting which patients have a high risk of tumor recurrence and can benefit from intensive treatment after surgery.
Severity kanker titik perlu dasarna diperkirakeun dumasar kana sumebarna sarta metastasis dina titik. Estimasi ieu aggressiveness kanker sarta résiko kambuh sanggeus perlakuan bakal ngaronjatkeun perlakuan. Mangtaun-taun, parantos dipercaya yén réspon imun pasien bakal ngagaduhan pangaruh anu mangpaat pikeun kanker. Panaliti panganyarna nunjukkeun yén invasi tumor kanker ku sél imun tiasa janten indikator anu hadé pikeun arah pangembangan kanker kolorektal, janten alat prognostik poténsial pikeun ngaidentipikasi populasi sél imun kalayan inpormasi anu paling seueur ngeunaan kamajuan panyakit.
Nyiptakeun tés imunologis ieu cocog pikeun prakték klinis. Gawéna ku ngitung kapadetan dua sél imun dina tumor sareng margin invasi na: sél T total (CD3 +) sareng sél T killer (CD8 sitotoksik). Panilitian ieu ngaevaluasi nilai prognostik pasién anu kanker skala ageung pisan, kalebet 2681 pasién ti pusat anu béda. Numutkeun résiko kambuh (5 taun saatos operasi) sareng penilaian tingkat salamet, penderita dibagi kana tilu kelompok (skor tinggi, sedeng sareng handap) imun pikeun ngaduga kinerja prognostik. Hasilna nunjukkeun yén pasién anu ngagaduhan skor imun tinggi nampilkeun résiko paling handap tina kambuh sareng waktos salamet anu langkung lami.
Of the 700 patients, only 8% of patients with high scores relapsed after 5 years. However, the relapse rate of patients with middle and low scores increased significantly, reaching 19% and 32%, respectively. These findings indicate that the immune score provides an accurate and reliable assessment of the risk of colon cancer recurrence. Use the risk of recurrence to improve individual patient treatment strategies, especially changes in chemotherapy regimens. In view of the highly positive results of colon cancer, immunoscore tests for other cancers are under way, which will revolutionize the treatment of cancer patients.
